Last updated: February 21, 2026
What is NDC 83324-0060?
NDC 83324-0060 is a drug marketed as Fingolimod (Gilenya), indicated primarily for the treatment of relapsing forms of multiple sclerosis (MS). It is an immunomodulator that reduces the frequency of MS relapses by modulating lymphocyte migration.
Market Overview
The MS treatment market historically sees steady demand driven by increasing diagnoses and the approval of novel therapies. Fingolimod’s market position is influenced by its approval date (2010 by the FDA) and its status as a first oral therapy for MS, which attracted market share early on.
Market Size (2022)
- Global MS therapeutics market: approximately $23 billion[1].
- Fingolimod’s share (2022): approximately $3.2 billion, accounting for about 14% of the MS drugs market[2].
Competitive Landscape
- ATP competitors include dimethyl fumarate (Tecfidera), ocrelizumab (Ocrevus), and natalizumab (Tysabri).
- New entrants such as oral sphingosine 1-phosphate receptor modulators (e.g., ozanimod) are gaining market share.
- Patent protection for Fingolimod expires in the US in late 2024, opening the market for generics.
Key Drivers
- Increasing MS prevalence: estimated at 2.8 million globally[3].
- Growing awareness and diagnosis rates.
- Preference for oral therapies over injectables.
- Expansion into evolving markets (e.g., China, India).
Price Trends and Projections
Current Pricing
- Brand Name (Gilenya): Average wholesale price (AWP): approximately $7,200 per 30-day supply (varies by insurer and tier).
- Generics (expected post-2024): projected to reduce costs by 40-60%.
Market Dynamics Influencing Prices
- Patent expiration forecast: late 2024.
- Post-patent market entry: generic versions may drop prices to $3,000-$4,500 per 30-day supply.
- Insurance coverage and formulary placement influence net price.
Price Projection (2023–2027)
| Year |
Brand Price (per 30-day supply) |
Generic Price (post-2024) |
Notes |
| 2023 |
$7,200 |
Not applicable |
Patent protection remains in place |
| 2024 |
$7,200 |
Price drops begin |
Patent expiration approaches |
| 2025 |
$6,500–$7,200 |
$3,000–$4,500 |
Increased generic market entry |
| 2026 |
$6,000–$6,800 |
$2,500–$4,000 |
Higher market penetration |
| 2027 |
$5,500–$6,300 |
$2,000–$3,500 |
Stabilization with competition |
Future Market Impact
Post-2024, pricing pressures are expected to significantly reduce costs. The degree of price erosion depends on the number of generic entrants, payer negotiations, and formulary inclusions.
Regulatory and Policy Factors
- Patent litigation: Possible extensions or delays.
- Pricing regulations: Emerging policies could influence pricing strategies and reimbursement.
- Market access: Countries like China and India may see earlier generic adoption due to local regulations.
Summary
- NDC 83324-0060 (Fingolimod) commands a high brand price ($7,200 per month) due to its market exclusivity, with significant price erosion anticipated after patent expiry.
- Market share remains steady, driven by patient preference for oral MS therapies.
- Price reductions will benefit payers and increase uptake in price-sensitive markets.
Key Takeaways
- The drug's current monopoly pricing is high; generics will introduce competitive pricing post-2024.
- MS prevalence growth sustains demand, underpinning price stability pre-patent expiry.
- Market competition and regulatory policies will influence future forecasts.
FAQs
1. When does patent expiry occur for Fingolimod?
Late 2024 in the US, enabling generic manufacturing.
2. How much will prices decline post-patent?
Delivery prices are projected to fall by 40–60%, reaching approximately $3,000 per 30-day supply.
3. What factors could delay generic entry?
Patent litigation, market exclusivity extensions, or regulatory hurdles.
4. Are there equivalent oral MS therapies?
Yes, ozanimod, ponesimod, and siponimod are oral alternatives gaining market share.
5. How do pricing trends vary across markets?
Developed countries maintain higher prices, while emerging markets adopt lower prices faster due to regulatory policies and local manufacturing.
References
[1] MarketWatch. (2022). MS therapeutics market size.
[2] IQVIA. (2022). Global MS drug sales report.
[3] Multiple Sclerosis International Federation. (2022). Atlas of MS.
